At Week 8 after starting dabrafenib/trametinib, participant will have MRI and/or CT scans of participant's brain to check the status of the disease. Participant will also have CT scans of the chest, abdomen, and pelvis. If the scans show the disease has not spread or grown, participant will be scheduled for surgery. Participant will continue taking the study drugs until the day of participant's surgery.